While it is well-established that colorectal tumors with CDX2 expression have better overall and cancer-specific survival rates, the prognostic impact of CDX2 on gynecological tumors, including UCS, is underexplored [25]. This evidence concerns the gene CDX2 and colorectal neoplasm.